1/16/2014 9:30:06 AM
DUBLIN--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced that it has completed the sale of its Confluent Surgical product line to Integra LifeSciences Corporation for approximately $235 million in cash. In addition, Covidien may receive up to an additional $30 million, contingent upon the achievement of certain performance measures related to the transition of the Confluent Surgical product line to Integra.
Help employers find you! Check out all the jobs and post your resume.
comments powered by